

**Body mass index and risk of non-alcoholic fatty liver disease: Two electronic health record  
prospective studies**

A. Katrina Loomis<sup>1</sup>, Shaum Kabadi<sup>1</sup>, David Preiss<sup>2</sup>, Craig Hyde<sup>1</sup>, Vinicius Bonato<sup>1</sup>, Matthew St. Louis<sup>1</sup>,  
Jigar Desai<sup>3</sup>, Jason M.R. Gill<sup>2</sup>, Paul Welsh<sup>2</sup>, Dawn Waterworth<sup>3</sup>, Naveed Sattar<sup>2</sup>

<sup>1</sup>Pfizer Worldwide Research and Development, Groton, CT; Pfizer Worldwide Research and  
Development, New York, NY; <sup>2</sup>BHF Glasgow Cardiovascular Research Centre University of Glasgow,  
Glasgow, G12 8TA; Cardiovascular, <sup>3</sup>Metabolic and Dermatology Genetics Unit, GlaxoSmithKline, King  
of Prussia, PA

**Abbreviated title:** BMI and risk of future NAFLD

**Key terms:** body mass index, obesity, nonalcoholic fatty liver disease, non-alcoholic steatohepatitis, risk  
factor

**Word count:** 3434

**Number of Tables and Figures:** 5

**Corresponding Authors:** Naveed Sattar, Institute of Cardiovascular and Medical Sciences, British Heart  
Foundation Glasgow, Cardiovascular Research Centre, University of Glasgow. Email:

[Naveed.sattar@glasgow.ac.uk](mailto:Naveed.sattar@glasgow.ac.uk)

Or Katrina Loomis, Pharma Therapeutics Clinical Research, Pfizer Worldwide Research and  
Development. Email: [Katrina.Loomis@Pfizer.com](mailto:Katrina.Loomis@Pfizer.com)

**Funding:** Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115372, composed  
of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013)  
and EFPIA companies' in kind contribution. P. Welsh is supported by BHF fellowship FS/12/62/29889

**Disclosure Summary:** The authors have nothing to disclose

## Abstract

**Context:** The relationship between rising body mass index (BMI) and *prospective* risk of non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH) is virtually absent.

**Objective:** Determine the extent of the association between BMI and risk of future NAFLD diagnosis, stratifying by sex and diabetes.

**Design:** Two prospective studies using Humedica and THIN with 1.54 and 4.96 years of follow-up respectively.

**Setting:** Electronic health record databases

**Participants:** Patients with had a recorded BMI measurement between 15-60kg/m<sup>2</sup>, and smoking status, and one year of active status prior to baseline BMI. Patients with a diagnosis or history of chronic diseases were excluded.

**Interventions:** None

**Main Outcome Measure:** Recorded diagnosis of NAFLD/NASH during follow-up (Humedica ICD-9 code 571.8, and read codes for NAFLD and NASH in THIN).

**Results:** Hazard ratios (HR) were calculated across BMI categories using BMI of 20–22.5kg/m<sup>2</sup> as the reference category, adjusting for age, sex and smoking status. Risk of recorded NAFLD/NASH increased linearly with BMI and was approximately 5-fold higher in Humedica (HR=4.78, 95% CI 4.17-5.47) and 9-fold higher in THIN (HR=8.93, 7.11-11.23) at a BMI of 30-32.5 kg/m<sup>2</sup> rising to around 10-fold higher in Humedica (HR=9.80, 8.49-11.32) and 14-fold higher in THIN (HR=14.32, 11.04-18.57) in the 37.5-40 kg/m<sup>2</sup> BMI category. Risk of NAFLD/NASH was approximately 50% higher in men, and approximately double in those with diabetes.

**Conclusions:** These data quantify the consistent and strong relationships between BMI and *prospectively* recorded diagnoses of NAFLD/NASH and emphasize the importance of weight reduction strategies for prevention and management of NAFLD.

## Introduction

Non-alcoholic fatty liver disease (NAFLD) is currently the most common form of liver disease and abnormal liver function tests and its prevalence is increasing due to the rise in obesity (1). Progression of NAFLD may lead to non-alcoholic steatohepatitis (NASH), marked by inflammation of the liver, and can further progress to fibrosis and eventual cirrhosis. Although simple NAFLD is usually benign and does not frequently progress to more advanced stages of liver disease, because of its high prevalence it is an increasing public health concern and a leading cause of cirrhosis (2, 3). The estimated prevalence of NAFLD and NASH in the general population varies based on diagnostic method: NAFLD prevalence is estimated to be between 6.3 and 33% and NASH around 3-5% (4). Prevalence of NAFLD among patients with type 2 diabetes has been estimated as high as 69% based on ultrasound diagnosis (5). Accurate prevalence of NASH is more difficult to estimate because liver biopsy is required and thus systematic screening or prospective study in the general population is not possible (6). Recorded diagnosis of NAFLD is currently the only realistic option of attaining detailed data on incident NAFLD in large studies, accepting many cases of NAFLD will not be picked up due to lack of systematic screening in any country.

While there is wide appreciation of the link between obesity and risk of both NAFLD and NASH, almost exclusively from cross-sectional studies, large prospective epidemiological studies prospectively linking obesity to *incident* NAFLD/NASH are limited, save a recent study in Chinese subjects in a 5 year follow-up of 5562 normal weight subjects (7), and prior evidence linking obesity with higher risk for incident cirrhosis (8). Such studies are important scientifically for clinical management strategies and for public health information. For example, previously reported data from large prospective studies suggest BMI  $\geq 35$  kg/m<sup>2</sup> is associated with a ~40 to 90-fold increased diabetes risk compared to reference groups with BMI <22-23kg/m<sup>2</sup> (9, 10). This provides benchmarks for clinical management and public health guidance beyond cross-sectional data, and as such these latter two studies are widely cited. One would anticipate that the association between BMI and incident NAFLD/NASH is likewise strong though the prospective

evidence is limited. Obesity, type 2 diabetes, and insulin resistance are closely linked to NAFLD (11) and weight loss and increased physical activity are associated with reductions in liver fat (12, 13).

In this study, using large prospective routinely collected data (comprising >2.1 million people) we report the relationship between BMI and risk of a “recorded” NAFLD/NASH diagnosis using two large electronic health record (EHR) databases, additionally stratifying by diabetes status and sex, to explore issues potentially informative to future clinical guidelines on management of these conditions. Of course, many patients with NAFLD are not picked in the real world up due to a variety of reasons and, as such, our study also provides a useful estimate of NAFLD recording in real clinical practice.

## **Materials and Methods**

### ***Databases and analytical sample ascertainment***

This study was performed using EHR data from two large databases: The Health Improvement Network (THIN) database and Humedica EHR database. THIN is a UK primary care EHR data resource including more than 12 million total patients, of whom more than 3 million are current patients. Patient data in THIN are collected from UK general practitioners (GP) and represent approximately 6% of the total UK population. During each consultation between the GP/nurse and patient, all conditions and symptoms are recorded electronically using the Read Clinical Classification version 2. Participants are representative of the UK population by age, gender and medical conditions (14). THIN data were acquired from Cegedim Strategic Data Medical Research (UK) which licenses the record-level anonymized data collected from the National Health Service for use in medical research. The analyses described herein included current and past patients with records available in the years of 2003-2013. The Humedica EHR database contains information on approximately 25 million patients, 7 million of whom have integrated outpatient and hospital records. Medical conditions are recorded using ICD-9 codes. Our analysis used data from general practitioners, specialty care and hospitalizations in the years of 2007-2013. Our prospective

analyses were limited to patients with a recorded BMI measurement between 15-60kg/m<sup>2</sup>, and between the ages of 20-85 years for Humedica and ages 20-90 years for THIN. Patients without any recorded BMI measurement or without recorded smoking status were excluded. One year of active patient status was required prior to baseline BMI information in an effort to ensure disease history was captured. Patients with a diagnosis or history of chronic disease (including cardiovascular disease, neurodegenerative disease, chronic respiratory disease, neoplastic disease, or fatty liver disease) prior to baseline BMI date were excluded from analysis in an effort to reduce the impact of chronic diseases commonly associated with weight loss or non-BMI based risk on our endpoint of interest. Lack of reliable information about patient alcohol intake prevented the specific exclusion of patients with a history of alcohol abuse that may have been inaccurately diagnosed with NAFLD/NASH. However, the coding of NAFLD/NASH diagnosis implies that potential excessive alcohol intake was considered, and rejected, as a cause of liver disease at the time the diagnosis was recorded. The final analytical sample and details on the inclusion/exclusion criteria for patients in our sample are described in Figure 1 and the supplementary materials.

### ***Endpoints***

The outcome endpoint for analysis was a recorded diagnosis of NAFLD or NASH (see Supplemental Table 1). In Humedica, the outcome endpoint was determined by the ICD-9 code 571.8 which is specific for non-alcoholic liver disease and includes both NAFLD and NASH. In THIN, the outcome endpoint was determined using a combination of Read codes for NAFLD and NASH. Diabetes category in the analytical sample was defined as a patient receiving a diabetes diagnosis (either type 1 or type 2) where the diagnosis occurred anytime earlier than one year after the baseline BMI date and before the diagnosis of NAFLD/NASH. Diabetes status was determined in Humedica by the ICD-9 code 250.xx, and in THIN by the read codes C10EXXX and C10FXXX. The vast majority of cases (~90%) of diabetes are likely to be Type 2 diabetes.

### ***Statistical analysis***

Cox proportional hazards ratios and 95% confidence intervals for the recording of a diagnosis of NAFLD/NASH were calculated across BMI categories in patients in the analytical sample. Patients were grouped in 10 BMI categories at baseline ranging between 15 and 60kg/m<sup>2</sup>. BMI category 20 to <22.5kg/m<sup>2</sup> was selected as the reference category. The proportional hazards assumptions for all BMI categories in all performed models were tested and confirmed. The statistical model was adjusted for age (continuous variable), sex (male or female), and smoking status (categorical variable for never smoker, former smoker, and current smoker). The analysis was conducted using all patients meeting the inclusion criteria and it was then repeated after stratifying patients based on diabetes status and sex respectively. Stratified analyses allowed for an interaction term between diabetes or sex and the BMI categories.

In order to assess potential bias we compared the BMI distribution of the analytical sample in each database with the published BMI distribution for each country. All statistical analyses were conducted using R version 3.1.2.

## **Results**

### ***Patient characteristics***

More than 50% of patients in each database had a recorded measurement of BMI (Figure 1). Patient characteristics for the analytical sample are provided in Table 1 and the data supplement (supplement Fig 1). Age, sex, smoking status and prevalence of diabetes were broadly similar between the two databases. The median follow-up time in the analytical sample was longer in THIN compared to Humedica (4.96 (IQR 2.26-7.55) vs. 1.54 (IQR 0.7–2.48) years). Average BMI ( $\pm$ SD) was higher in Humedica than THIN (28.14 $\pm$ 6.43 vs 26.81 $\pm$ 5.57kg/m<sup>2</sup>). During the study, 8,342 NAFLD/NASH cases were recorded in Humedica and 2,989 in THIN. In the latter cohort, around only ~5% had incident NASH (precluding meaningful stratified analyses) and the remainder had incident NAFLD.

### ***Relationship between BMI and NAFLD or NASH diagnosis***

Risk of a recorded NAFLD/NASH diagnosis increased approximately linearly with increasing BMI in both the Humedica and THIN patient databases from the reference BMI category (20 to <22.5kg/m<sup>2</sup>) through to BMI category 37.5 to <40kg/m<sup>2</sup> (Figure 2). Risk of NAFLD/NASH diagnosis was approximately 9-fold higher in THIN (HR=8.93, 95% CI: 7.11-11.23) and 5-fold higher in Humedica (4.78, 4.17-5.47) at a BMI of 30-32.5 kg/m<sup>2</sup> (Figure 2). These risks continued to rise to around 14-fold higher in THIN (HR=14.32, 11.04-18.57) and 10-fold higher in Humedica (HR=9.80, 8.49-11.32) in the 37.5-40 kg/m<sup>2</sup> BMI category compared to the reference category. In THIN, the HR per one unit increment BMI was 1.16 (95% CI: 1.116-1.17) and in Humedica it was 1.14 (95% CI: 1.14-1.15).

### ***Sex-stratified analysis***

In the sex-stratified analysis (Figure 3), men had greater risk of NAFLD/NASH diagnosis compared to women at every BMI category. The BMI-adjusted HR for men compared to women was 1.58 in THIN (CI: 1.47-1.70) and 1.40 in Humedica (CI: 1.34-1.46). Furthermore, the relative risk of men vs women increased with increasing BMI, although this interaction tested as a linear effect across categories was significant only for Humedica (p=0.0159).

### ***Relationship between BMI and NAFLD/NASH in patients with or without diabetes***

In the analysis stratified by diabetes status, when patients were compared to the diabetes status-specific reference BMI category, we observed a greater association of increasing BMI on NAFLD/NASH diagnosis in patients without diabetes compared to diabetes patients (Figure 4a and 4c). In Humedica, patients without diabetes in the highest BMI category had a HR of >10 (HR=10.55, 9.12-12.20, supplementary Table 2) compared to the reference category, whereas in patients with diabetes the HR was approximately four (HR=3.67, 2.51-5.36). Results in THIN were broadly similar, and in both cases interaction terms were significant (p<0.00001). When patients with diabetes were compared to those without diabetes as the reference category with similar BMI, diabetes patients had HRs that were near

double those without diabetes for all BMI categories (above 27.5), whereas in the lower BMI categories the risk of NAFLD/NASH associated with diabetes was generally higher at around 3-5 fold (Figure 4b and 4d). This finding was consistent in both the Humedica and THIN databases such that patients with diabetes in the highest BMI category (40-60kg/m<sup>2</sup>) had a HR >20 (HR=21.63, 18.26-25.61 [Humedica]; HR=24.88, 16.65-37.19 [THIN]) compared to patients without diabetes in the reference BMI category. Overall, the risk of NAFLD/NASH diagnosis was 2-fold higher in patients with T2D compared to those without T2D after adjusting for BMI (THIN HR=1.96, 1.75-2.20; Humedica HR=2.30, 2.17-2.44).

### ***Evaluating the generalizability of our results***

The BMI in our analytical samples was broadly similar to published data during similar time periods in the UK (Health Survey for England 2012) (15) and US (NHANES 2011-2012) (16) (supplement Fig2).

## **Discussion**

This study provides two important findings. Firstly, that irrespective of limited pick up of NAFLD in the real world, the prospective risk for being recorded as having a diagnosis of NAFLD/NASH increased linearly with increasing BMI such that risk of NAFLD/NASH diagnosis was approximately 5 to 9 fold higher at BMI of 30-32.5 kg/m<sup>2</sup> rising to rise to around 10 to 14-fold higher at BMIs of 37.5-40 kg/m<sup>2</sup> compared to patients with BMI 20-22.5 kg/m<sup>2</sup>. Second, in both databases the baseline prevalence of NAFLD/NASH was a fraction of the estimated population prevalence in prior studies which employed systematic hepatic imaging (17, 18). This finding is expected and suggests that NAFLD is either being missed or not looked for in many patients in the real world.

Despite differences in clinical practice in the UK compared to the US, and just over a 1kg/m<sup>2</sup> difference in average baseline BMI and difference in average follow-up duration, relative risks of NAFLD/NASH diagnosis by BMI in both EHR databases were broadly similar, even though the follow-up times were limited in THIN. We also showed that *relative* increases in risk for recorded NAFLD/NASH diagnosis



according to BMI were greater in individuals without diabetes compared to those with diabetes; not unexpected since many diabetes patients are likely to have NAFLD at diagnosis, even those at lower BMI. However, *absolute* risks were substantially higher in diabetes patients for any given BMI, a finding which supports the strong pathophysiological link (via ectopic fat) between NAFLD and type 2 diabetes (11). Indeed, it appears as if the association of diabetes with NAFLD/NASH risk is equivalent to a ~5-10 kg/m<sup>2</sup> increase in BMI in the non-diabetes curve; i.e. the curve is shifted substantially to the right. This is particularly evident in the HR for diabetes patients in the healthy BMI range (20-25 kg/m<sup>2</sup>) where the risk of recorded NAFLD/NASH was more than 5-fold compared to patients without diabetes.

These novel findings concur with expectations grounded almost predominantly in cross-sectional observations that ectopic liver fat is common in diabetes individuals at diagnosis (11, 19), but our findings also extend such observations by providing more granular data. Men had a modestly greater absolute risk of developing NAFLD/NASH in all BMI categories than women, data which fit with greater liver fat content in men and their higher risk of type 2 diabetes at most BMIs (20). Given the strength of the findings (in particular very high HRs at elevated BMIs), the size of the study, its prospective design, and its contextual consistency with other work, as discussed further below, our results are potentially valuable; physicians need to be aware of the strong and near linear relationship between BMI and NAFLD risk, and clinicians can relate to patients that weight is the most important risk factor for development of NAFLD.

We fully recognize that because fatty liver disease is often undiagnosed due to the lack of systematic screening, the relationship between BMI and a recorded diagnosis of NAFLD/NASH presented here does not necessarily reflect the true relationship. In both databases, the baseline prevalence was a fraction of the estimated population prevalence in prior studies which has employed imaging (17, 18). This discrepancy is likely due to the substantial under-diagnosis of NAFLD; routine screening procedures are not recommended in any country, and many patients with NAFLD are not recognised as having it since

liver function tests can be normal and even minor elevations are often not further investigated by imaging. Future studies are needed to determine if there is a temporal change in the recording of NAFLD diagnosis. We believe there will be as general physicians become more familiar with the relevant diagnostic algorithms.

Our results may reflect an underestimation of relative risks if more cases are being missed in overweight/obese individuals (where cross-sectional imaging studies show NAFLD to be much more common) or alternatively, there could be an overestimation of relative risks if a diagnosis of NAFLD is less likely to be sought in those with lower BMI. However, critically, several factors lead us to believe our results from these prospective analyses are reasonably robust and externally valid. Firstly, *cross-sectional* studies using imaging in adults and children show reports odds ratio for NAFLD by higher BMI which are in line with, or sometimes greater than, what we have shown for BMI vs incident NAFLD/NASH. For example, in the Third National Health and Nutrition Examination Survey, NAFLD prevalence ascertained by ultrasound was approximately around four to eight-fold higher in the obese as compared to normal weight individuals in different ethnicities, being greater in men than women, and greater in diabetes patients (21). Further, in our recent cross-sectional study of 1874 young males and females (mean age 17.9 years), the prevalence of fatty liver, ascertained by ultrasound in a careful and detailed manner, was 0.4% (5 of 1226), 4.3% (12 of 279), and 22.2% (26 of 117) for individuals who were normal, overweight, and obese, respectively i.e. more than a 50-fold risk in the obese (22). Secondly, the strong concordance between results from US-based and UK-based EHR databases, countries with different obesity rates and health care practices, increases our confidence in the conclusions. Thirdly, one prospective study in a Chinese population which repeated ultrasound yearly over five years in over 5500 subjects with around 500 incident NAFLD cases, noted a 13-fold difference in incidence risk comparing extreme fifths of BMI (1.53% vs 19.96%), even though the study was limited entirely to normal weight participants; notably the HR per 1 unit BMI in this Chinese study at 1.22 was slightly greater than what we observed at 1.14 and 1.16 in the two EHRs in adjusted analyses (7). Thus, if

anything, our findings of HRs in the present two EHRs ranging from 5-9 fold higher risks in obese (BMI of 30-32.5 kg/m<sup>2</sup>) to 10-14 fold in super obese (BMI 37.5-40 kg/m<sup>2</sup>) individuals relative to lean individuals (20-22.5kg/m<sup>2</sup>) appear consistent with cross-sectional findings, and if anything may potentially underestimate, rather than overestimate, risks. Fourthly, finding of HRs above 10 for NAFLD/NASH at higher levels of BMI also supports the associations likely being causal since such high HRs are unlikely to be simply due to bias or confounding (bias and confounding often obscure much weaker associations, ie. where HRs are <2-3 fold). Fifthly, higher risks of NAFLD/NASH in diabetes patients and in men are externally valid as they concord with cross-sectional imaging data, as described herein. Finally, we know modest weight loss (~5%) can lead to reductions in NAFLD (23) whereas more major weight loss (~10-15%) can substantially reduce NAFLD prevalence as demonstrated over a decade ago in a small series of diabetes patients (24), but an observation repeated many times since then, again in accordance with substantial HRs of risk at higher BMI levels.

Strengths and limitations of this work require careful consideration. The use of EHRs allowed us to access data from millions of patients, enabling us to study the relationship between BMI and NAFLD/NASH diagnosis in key patient sub-groups and, critically, in a much more granular fashion than previously attempted. Of course, an ideal study would measure liver fat levels (and all confounders) by imaging methods and then repeat these tests serially over time as incident cases appear. However such a study, conducted in the numbers required to adequately answer the question, does not exist as far as we know in a wide enough population to be generalisable. A further strength lies in our approach to limit sample bias through the exclusion of patients with chronic diseases linked to weight loss and adjusting for smoking status, both of which could confound the relationship between BMI and risk of NAFLD or NASH. Despite the benefits related to cost, timing, and access to large datasets, limited follow-up time and incomplete patient data represent two important limitations that can lead to bias. For example, in Humedica, patients without a recorded measurement of BMI had lower disease prevalence (data available on request). However, patients without BMI recorded are also likely to be thinner (thus health care

workers do not consider its measurement to be relevant) and at lower risk for complications. The relative low age of our cohort is perhaps a notable advantage given the lower potential for chronic diseases and thus less chance of bias. We did not have access to alcohol intake data to exclude cases of fatty liver disease that may have been inaccurately diagnosed. However, focusing on the NAFLD/NASH diagnosis should limit the impact of these patients in the results and implies that potential alcohol intake was considered, and rejected, as the main cause of liver disease at the time the diagnosis was recorded by a physician. Moreover, a recent a very recent *cross-sectional* study (25) which used similar ascertainment methods for NAFLD to ours (i.e. ICD coding) reported odds ratios, adjusted for alcohol intake, broadly similar to hazard ratios we report in our manuscript (obese vs normal weight OR=9.59). Hence, alcohol intake is unlikely to be a major bias in our study. We also recognize that future studies are needed to separately link BMI to incident NASH alone; we did not have sufficient power in the present cohorts to enable such analyses. Finally, the percentage of overweight and obese patients in our analytical sample is not dissimilar to published obesity rates for the US and UK during a similar time period (15, 16), giving our results some external applicability.

In summary, using two distinct EHR databases comprising >2.1 million people and >11,000 incident cases, we have shown two things. Firstly, that a strong and striking near linear relationship exists between BMI and future risk of ‘recorded’ NAFLD/NASH, with higher absolute risks in men and patients with diabetes. Second, that NAFLD recording rates are far lower than would expected from imaging studies, reflecting absence of systematic screening (currently not advocated) and relatively modest recognition of NAFLD. Nevertheless, as discussed the BMI-NAFLD relationship has strong external validity. The magnitude and consistency of the associations, namely a 5-10 fold increased risk in the obese and 10-14 fold risk in the morbidly obese highlights the importance of both prevention of weight gain and weight reduction strategies in the prevention and management of NAFLD.

**Ethics statement**

We had approval from both THIN and Humedica to perform analyses undertaken, all conducted on anonymized data as per their ethical agreements.

**Acknowledgements**

This work was supported by the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115372, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution. P. Welsh is supported by BHF fellowship FS/12/62/29889

## References

1. Marchesini G, Moscatiello S, Di Domizio S, Forlani G Obesity-associated liver disease. *J Clin Endocrinol Metab* 2008;93(11 Suppl 1):S74–80.
2. Dyson JK, Anstee QM, McPherson S: Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. *Frontline Gastroenterol* 2014;5:211–218.
3. Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, Ferguson J, Forton D, Foster G, Gilmore SI, Hickman M, Hudson M, Kelly D, Langford A, Lombard M, Longworth L, Martin N, Moriarty K, Newsome P, O’Grady J, Pryke R, Rutter H, Ryder S, Sheron N, Smith T. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. *Lancet* 2014;384:1953–97.
4. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology* 2012;55:2005–23.
5. Leite NC, Salles GF, Araujo ALE, Villela-Nogueira CA, Cardoso CRL. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. *Liver Int* 2009;29:113–9.
6. Gaidos JKJ, Hillner BE, Sanyal AJ: A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis. *Liver Int* 2008;28:650–8.
7. Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. *Am J Gastroenterol* 2013;108:1299–304.
8. Liu B, Balkwill A, Reeves G, Beral V. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. *BMJ* 2010;340:c912.
9. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes

- mellitus in women. *Ann Intern Med* 1995;122:481–6.
10. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. *Diabetes Care* 1994;17:961–9.
  11. Sattar N, Gill JMR. Type 2 diabetes as a disease of ectopic fat? *BMC Med* 2014;12 123.
  12. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. *J Hepatol* 2012;56:255–66.
  13. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. *Diabetologia* 2011;54:2506–14.
  14. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. *Inform Prim Care* 2011;19:251-5.
  15. Health Survey for England 2013. Health and social care information centre. Available from: [www.hscic.gov.uk/pubs/hse2012](http://www.hscic.gov.uk/pubs/hse2012)
  16. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity among adults: United States, 2011-2012. *JAMA*. 2014;311:806-14.
  17. Pan J-J, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. *World J Hepatol* 2014;6:274–83.
  18. Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, Srishord M. Nonalcoholic fatty liver disease in lean individuals in the United States. *Medicine (Baltimore)* 2012;91:319–27.
  19. Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. *BMJ* 2014;349:g4596.
  20. Logue J, Walker JJ, Colhoun HM, Leese GP, Lindsay RS, McKnight JA, Morris AD, Pearson DW, Petrie JR, Philip S, Wild SH, Sattar N. Do men develop type 2 diabetes at lower body mass indices than women? *Diabetologia* 2011;54:3003–6.
  21. Schneider ALC, Lazo M, Selvin E, Clark JM. Racial differences in nonalcoholic fatty liver disease in the U.S. population. *Obesity (Silver Spring)* 2014;22:292–9.

22. Lawlor DA, Callaway M, Macdonald-Wallis C, Anderson E, Fraser A, Howe LD, Day C, Sattar N. Nonalcoholic fatty liver disease, liver fibrosis, and cardiometabolic risk factors in adolescence: a cross-sectional study of 1874 general population adolescents. *J Clin Endocrinol Metab* 2014;99:E410–7.
23. Dyson J, Day C. Treatment of non-alcoholic fatty liver disease. *Dig Dis* 2014; 32:597–604.
24. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. *Diabetes* 2005;54:603–608.
25. Alazawi W, Mathur R, Abeysekera K, Hull S, Boomla K, Robson J, Foster GR. Ethnicity and the diagnosis gap in liver disease: a population-based study. *Br J Gen Pract* 2014;64:e694–702.



## Figure legends

Figure 1. Patient analytical sample for THIN (A) and Humedica (B).

Figure 2. Hazard ratios for diagnosis of NAFLD or NASH based on BMI category in Humedica (A) and THIN (B). Hazard ratios with 95% CI are presented compared to the reference BMI category of 20 to  $<22.5 \text{ kg/m}^2$ .

Figure 3. Hazard ratios for diagnosis of NAFLD or NASH based on BMI category stratified by sex in Humedica (A) and THIN (B). Hazard ratios with 95% CI are presented compared to the reference BMI category of 20 to  $<22.5 \text{ kg/m}^2$  in females.

Figure 4. Hazard ratios for diagnosis of NAFLD or NASH based on BMI category stratified by diabetes status in Humedica (A and B) and THIN (C and D). Hazard ratios with 95% CI are presented compared to the reference BMI category of 20 to  $<22.5 \text{ kg/m}^2$ . In plots A and C, HRs are based on the reference BMI category within that group. In plots B and D, HRs are based on the non-diabetic reference BMI category.

**Table 1.** Patient characteristics in the analytical sample for Humedica (2007-2013) and THIN (2003-2013).

Characteristic	Humedica n=1,048,934	THIN n=1,133,525
Age (years)	41.8±15.0	42.9±14.8
Sex (%)		
Male	390,916 (37.3)	467,540 (41.3)
Female	658,018 (62.7)	665,985 (58.8)
Smoking status (%)		
Current Smoker	350,622 (33.4)	251,410 (22.2)
Former Smoker	237,605 (22.7)	318,425 (28.1)
Never Smoker	460,707 (43.9)	563,690 (49.7)
Body mass index (kg/m <sup>2</sup> )	28.14±6.43	26.81±5.57
Follow-up time (years)	1.54 (0.70-2.48)	4.96 (2.26-7.55)
Diabetes category in analytical sample (%)		
Yes	50,104 (4.8)	45,582 (4.0)
No	998,830 (95.2)	1,087,943 (96.0)
Diagnosis of NASH/NAFLD after baseline	8342 (0.79%)	2989 (0.26%)

Data are presented as mean±standard deviation, median (interquartile range), or n(%).